|Bid||8.26 x 0|
|Ask||9.00 x 0|
|Day's Range||8.54 - 8.92|
|52 Week Range||6.61 - 10.47|
|Beta (3Y Monthly)||0.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Aurinia Pharmaceuticals Inc. today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT in New York, NY.
Aurinia Pharmaceuticals Inc.'s (TSE:AUP): Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company...
The Victoria, British Columbia-based company said it had a loss of 14 cents per share. Losses, adjusted for non-recurring gains, were 16 cents per share. The results matched Wall Street expectations. The ...
In recognition of Lupus Awareness Month and World Lupus Day, Aurinia Pharmaceuticals Inc. a late clinical-stage biopharmaceutical company with
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent […]
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it has appointed Dr. Daniel Billen to its Board of Directors. Dr. Billen’s appointment is effective April 29, 2019 concurrent with the previously announced appointment of Mr. Peter Greenleaf as Chief Executive Officer and elevation of Dr. George Milne to Chairman of the Board. “On behalf of the entire organization, it is a pleasure to welcome Daniel onto Aurinia’s Board of Directors.
Aurinia Pharmaceuticals Inc. today announced that members of the management team will present a corporate overview at the 2019 Bloom Burton & Co.
If you own shares in Aurinia Pharmaceuticals Inc. (TSE:AUP) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory consider...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr. Peter Greenleaf as Chief Executive Officer and as a Director on the Aurinia Board. The Company also announced the elevation of George M. Milne, Jr., Ph.D. to Chairman of the Board of Directors.
The Victoria, British Columbia-based company said it had a loss of 17 cents per share. The biotechnology company posted revenue of $29,000 in the period, missing Street forecasts. Three analysts surveyed ...
Aurinia Pharmaceuticals Inc. today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on the bright side, you canRead More...
In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a late clinical-stage biopharmaceutical company with research ongoing in two kidney diseases, Lupus Nephritis (LN) and Focal Segmental Glomerulosclerosis (FSGS), today announced a host of activities, including an initiative with The National Kidney Foundation (NKF), designed to raise awareness for kidney disease.
Aurinia Pharmaceuticals Inc. today announced that it will release its fourth quarter and full year 2018 financial results on Tuesday, March 19, 2019, after the market closes.
Aurinia Pharmaceuticals Inc. today announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on November 30, 2018, in relation to at-the-market offerings of common shares in the capital of the Company, the Company has completed the sale of 4,608,409 common shares at a weighted average price of US$6.55 for aggregate gross proceeds of approximately US$30 million....
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/ TSX:AUP) (the “Company” or “Aurinia”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. patent application 15/835,219, entitled “PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS”. The allowed claims broadly cover the novel voclosporin dosing protocol adhered to and required in both the previously reported Phase II AURA-LV study and the ongoing Phase III confirmatory AURORA study.
Aurinia Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference in NYC on February 27, 2019 at 2:30pm ET.
Small-cap biotech Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) fell Tuesday morning following the release of clinical trial results. What Happened Aurinia said a mid-stage study that evaluated its dry eye ...